-2.24%
-10.45%
-21.12%
-16.12%
12.05%
-74.80%
-41.73%
AI Spotlight on LPCN
Company Description
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders.The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs.Its lead product candidate is TLANDO, an oral testosterone replacement therapy.
The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth.The company is headquartered in Salt Lake City, Utah.
Market Data
| Last Price | 4.37 |
| Change Percentage | -2.24% |
| Open | 4.49 |
| Previous Close | 4.47 |
| Market Cap ( Millions) | 23 |
| Volume | 31269 |
| Year High | 11.79 |
| Year Low | 3.2 |
| M A 50 | 4.81 |
| M A 200 | 5.38 |
Financial Ratios
| FCF Yield | -21.54% |
| Dividend Yield | 0.00% |
| ROE | -19.17% |
| Debt / Equity | 0.00% |
| Net Debt / EBIDTA | 75.64% |
| Price To Book | 1.22 |
| Price Earnings Ratio | -5.76 |
| Price To FCF | -4.64 |
| Price To sales | 2.95 |
| EV / EBITDA | -3.97 |
News
- Dec -17 - FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
- Nov -18 - Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session
- Nov -07 - Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024
- Oct -31 - Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea
- Oct -10 - Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results
- Oct -08 - Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries
- Oct -02 - Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024
- Sep -30 - Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference
- Sep -05 - Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
- Aug -27 - Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Aug -08 - Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024
- Jun -25 - Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study
- Jun -10 - Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024
- Jun -06 - Lipocine (LPCN) Is a Great Choice for 'Trend' Investors, Here's Why
- May -28 - 7 Penny Biotech Stocks to Triple Your Investment
- May -21 - Here's Why Momentum in Lipocine (LPCN) Should Keep going
- May -09 - Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
- May -08 - Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
- May -01 - Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
- Apr -11 - Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Oral Delivery Solutions
Expected Growth : 8.9 %
What the company do ?
Lipocine Inc.'s Oral Delivery Solutions enhance bioavailability of poorly absorbed drugs by creating crystalline forms that improve solubility and permeability.
Why we expect these perspectives ?
Lipocine Inc.'s Oral Delivery Solutions exhibit 8.9% growth driven by increasing demand for convenient, patient-centric treatments, advancements in lipid-based formulations, and strategic partnerships expanding market reach. Additionally, growing prevalence of chronic diseases, such as hypogonadism and thyroid disorders, fuels adoption of oral delivery solutions.
Lipocine Inc. Products
| Product Range | What is it ? |
|---|---|
| TLANDO | TLANDO is an oral testosterone replacement therapy (TRT) for the treatment of hypogonadism in adult males. |
| LPCN 1021 | LPCN 1021 is an oral hydrocortisone (cortisol) replacement therapy for the treatment of congenital adrenal hyperplasia (CAH) and adrenal insufficiency. |
| LPCN 1111 | LPCN 1111 is an oral testosterone therapy for the treatment of vasomotor symptoms in men, including hot flashes and night sweats. |
| LPCN 1107 | LPCN 1107 is an oral therapy for the treatment of non-alcoholic steatohepatitis (NASH). |
Lipocine Inc.'s Porter Forces
Threat Of Substitutes
Lipocine Inc. has a moderate threat of substitutes due to the presence of alternative treatments for hypogonadism, such as testosterone gels and patches. However, the company's oral testosterone replacement therapy has a unique advantage in terms of convenience and patient compliance.
Bargaining Power Of Customers
Lipocine Inc.'s customers, primarily healthcare providers and patients, have limited bargaining power due to the company's specialized product offerings and limited competition in the oral testosterone replacement therapy market.
Bargaining Power Of Suppliers
Lipocine Inc. relies on a limited number of suppliers for its raw materials and manufacturing services, which gives them some bargaining power. However, the company's strong relationships with its suppliers and its ability to negotiate contracts mitigate this risk.
Threat Of New Entrants
The threat of new entrants in the oral testosterone replacement therapy market is high due to the attractiveness of the market and the potential for new companies to enter with innovative products or technologies.
Intensity Of Rivalry
The intensity of rivalry in the oral testosterone replacement therapy market is moderate, with a few established players competing for market share. However, Lipocine Inc.'s unique product offerings and strong relationships with healthcare providers give it a competitive advantage.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 0.08% |
| Debt Cost | 3.95% |
| Equity Weight | 99.92% |
| Equity Cost | 9.39% |
| WACC | 9.39% |
| Leverage | 0.08% |
Lipocine Inc. : Quality Control
Lipocine Inc. passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| FULC | Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in … |
| CLSD | Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone … |
| EYPT | EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, … |
| ABUS | Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of … |
| RIGL | Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Arbutus Biopharma
A-Score
1-Year Total Return ->
🥈
Lipocine
A-Score
1-Year Total Return ->
🥉
Rigel Pharma
A-Score
1-Year Total Return ->
4
Clearside Biomedical
A-Score
1-Year Total Return ->
5
EyePoint Pharmaceuticals
A-Score
1-Year Total Return ->
6
